Disproportionality analysis of adverse neurological and psychiatric reactions with the ChAdOx1 (Oxford-AstraZeneca) and BNT162b2 (Pfizer-BioNTech) COVID-19 vaccines in the United Kingdom.
Matilde Otero-LosadaNikolai PetrovskyAbdallah AlamiJames A CrispoDonald MattisonFrancisco CapaniChristopher GoetzDaniel KrewskiSantiago Perez-LloretPublished in: Expert opinion on drug safety (2022)
Neurological and psychiatric AEFIs were relatively infrequent, but each vaccine was associated with a distinctive toxic profile.